These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38763866)

  • 41. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
    Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
    Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating the Use of Dalbavancin for Off-Label Indications.
    Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
    Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk for infective endocarditis in bacteremia with Gram positive cocci.
    Andersen MH; Holle SLK; Klein CF; Bruun NE; Arpi M; Bundgaard H; Tønder N; Iversen KK
    Infection; 2020 Dec; 48(6):905-912. PubMed ID: 32844380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
    Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
    Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
    Sader HS; Mendes RE; Pfaller MA; Flamm RK
    J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The current and future off-label uses of dalbavancin: a narrative review.
    De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.
    Buzón Martín L; Mora Fernández M; Perales Ruiz JM; Ortega Lafont M; Álvarez Paredes L; Morán Rodríguez MA; Fernández Regueras M; Machín Morón MA; Mejías Lobón G
    Rev Esp Quimioter; 2019 Dec; 32(6):532-538. PubMed ID: 31642637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Performance of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis in Relation to the Modified Duke Criteria and to Clinical Management-Reanalysis of Retrospective Bacteremia Cohorts.
    Lindberg H; Berge A; Jovanovic-Stjernqvist M; Hagstrand Aldman M; Krus D; Öberg J; Kahn F; Bläckberg A; Sunnerhagen T; Rasmussen M
    Clin Infect Dis; 2024 Apr; 78(4):956-963. PubMed ID: 38330240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of endocarditis among patients with coagulase-negative Staphylococcus bacteremia.
    Ramos-Martínez A; González-Merino P; Suanzes-Martín E; la Fuente MM; Escudero-López G; Andrés-Eisenhofer A; Expósito-Palomo E; Gutierrez-Villanueva A; Diego-Yagüe I; Múñez E; Fernandez-Cruz A; Calderón-Parra J
    Sci Rep; 2023 Sep; 13(1):15613. PubMed ID: 37730691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.
    Segreti JA; Crank CW; Finney MS
    Pharmacotherapy; 2006 Mar; 26(3):347-52. PubMed ID: 16503714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study.
    Østergaard L; Bruun NE; Voldstedlund M; Arpi M; Andersen CØ; Schønheyder HC; Lemming L; Rosenvinge F; Valeur N; Søgaard P; Andersen PS; Skov R; Chen M; Iversen K; Gill S; Lauridsen TK; Dahl A; Oestergaard LB; Povlsen JA; Moser C; Bundgaard H; Køber L; Fosbøl EL
    Eur Heart J; 2019 Oct; 40(39):3237-3244. PubMed ID: 31145782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transmission of infection to liver transplant recipients from donors with infective endocarditis: lessons learned.
    Miceli MH; Gonulalan M; Perri MB; Samuel L; Al Fares MA; Brown K; Bruno DA; Zervos M; Ramesh M; Alangaden G
    Transpl Infect Dis; 2015 Feb; 17(1):140-6. PubMed ID: 25586791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.
    Stewart CL; Turner MS; Frens JJ; Snider CB; Smith JR
    Infect Dis Ther; 2017 Jun; 6(2):277-289. PubMed ID: 28386776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
    Hakim A; Braun H; Thornton D; Strymish J
    Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infective endocarditis - can we treat it more effectively?
    Guzek A; Braksator W; Gąsior Z; Kuśmierczyk M; Różański J; Rybicki Z
    Kardiochir Torakochirurgia Pol; 2020 Mar; 17(1):8-14. PubMed ID: 32728356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Potential indications of dalbavancin in clinical practice].
    Barberán J
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():38-40. PubMed ID: 28129820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relevance of [
    Hualde AM; Mantilla JA; Rincón JO; Regí AR; Kestler M; Muñoz P; Delgado-Montero A; Cuerpo-Caballero G; Pinilla B; Alonso Farto JC;
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(3):139-146. PubMed ID: 36309202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.